These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 38157159)

  • 21. Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis.
    Melenovsky V; Petrak J; Mracek T; Benes J; Borlaug BA; Nuskova H; Pluhacek T; Spatenka J; Kovalcikova J; Drahota Z; Kautzner J; Pirk J; Houstek J
    Eur J Heart Fail; 2017 Apr; 19(4):522-530. PubMed ID: 27647766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic iron deficiency does not affect the cardiac iron content and progression of heart failure.
    Paterek A; Oknińska M; Chajduk E; Polkowska-Motrenko H; Mączewski M; Mackiewicz U
    J Mol Cell Cardiol; 2021 Oct; 159():16-27. PubMed ID: 34139233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitochondrial Fusion, Fission, and Mitophagy in Cardiac Diseases: Challenges and Therapeutic Opportunities.
    Scheffer DDL; Garcia AA; Lee L; Mochly-Rosen D; Ferreira JCB
    Antioxid Redox Signal; 2022 May; 36(13-15):844-863. PubMed ID: 35044229
    [No Abstract]   [Full Text] [Related]  

  • 24. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function.
    Hoes MF; Grote Beverborg N; Kijlstra JD; Kuipers J; Swinkels DW; Giepmans BNG; Rodenburg RJ; van Veldhuisen DJ; de Boer RA; van der Meer P
    Eur J Heart Fail; 2018 May; 20(5):910-919. PubMed ID: 29484788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ferroptosis Is Regulated by Mitochondria in Neurodegenerative Diseases.
    Zhou J; Jin Y; Lei Y; Liu T; Wan Z; Meng H; Wang H
    Neurodegener Dis; 2020; 20(1):20-34. PubMed ID: 32814328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous iron in heart failure and chronic kidney disease.
    Carrilho P
    Nefrologia (Engl Ed); 2021; 41(4):403-411. PubMed ID: 36165109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Puerarin protects against heart failure induced by pressure overload through mitigation of ferroptosis.
    Liu B; Zhao C; Li H; Chen X; Ding Y; Xu S
    Biochem Biophys Res Commun; 2018 Feb; 497(1):233-240. PubMed ID: 29427658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T2* magnetic resonance and myocardial iron in thalassemia.
    Pennell DJ
    Ann N Y Acad Sci; 2005; 1054():373-8. PubMed ID: 16339685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications.
    Chuang TY; Li JP; Weng TF; Wu KH; Chao YH
    Ann Hematol; 2020 Oct; 99(10):2289-2294. PubMed ID: 32737633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Omentin1 ameliorates myocardial ischemia-induced heart failure via SIRT3/FOXO3a-dependent mitochondrial dynamical homeostasis and mitophagy.
    Hu J; Liu T; Fu F; Cui Z; Lai Q; Zhang Y; Yu B; Liu F; Kou J; Li F
    J Transl Med; 2022 Oct; 20(1):447. PubMed ID: 36192726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial.
    Rosano G; Ponikowski P; Vitale C; Anker SD; Butler J; Fabien V; Filippatos G; Kirwan BA; Macdougall IC; Metra M; Ruschitzka F; Kumpeson V; Goehring UM; van der Meer P; Jankowska EA;
    Cardiovasc Diabetol; 2023 Aug; 22(1):215. PubMed ID: 37592272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure.
    Haddad S; Wang Y; Galy B; Korf-Klingebiel M; Hirsch V; Baru AM; Rostami F; Reboll MR; Heineke J; Flögel U; Groos S; Renner A; Toischer K; Zimmermann F; Engeli S; Jordan J; Bauersachs J; Hentze MW; Wollert KC; Kempf T
    Eur Heart J; 2017 Feb; 38(5):362-372. PubMed ID: 27545647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isorhapontigenin Attenuates Cardiac Microvascular Injury in Diabetes via the Inhibition of Mitochondria-Associated Ferroptosis Through PRDX2-MFN2-ACSL4 Pathways.
    Chen Y; Li S; Yin M; Li Y; Chen C; Zhang J; Sun K; Kong X; Chen Z; Qian J
    Diabetes; 2023 Mar; 72(3):389-404. PubMed ID: 36367849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beneficial effects of intravenous iron therapy in a rat model of heart failure with preserved systemic iron status but depleted intracellular cardiac stores.
    Paterek A; Kępska M; Sochanowicz B; Chajduk E; Kołodziejczyk J; Polkowska-Motrenko H; Kruszewski M; Leszek P; Mackiewicz U; Mączewski M
    Sci Rep; 2018 Oct; 8(1):15758. PubMed ID: 30361476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential role of prolyl hydroxylases on mitochondrial function of HL-1 cells in a model of iron deficiency.
    Kandilci HB; Şimşek G; Zirapli T; Çelebier M
    Mitochondrion; 2022 Mar; 63():51-56. PubMed ID: 35066139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of iron overload, an iron chelator and a T-Type calcium channel blocker on cardiac mitochondrial biogenesis and mitochondrial dynamics in thalassemic mice.
    Khamseekaew J; Kumfu S; Wongjaikam S; Kerdphoo S; Jaiwongkam T; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N
    Eur J Pharmacol; 2017 Mar; 799():118-127. PubMed ID: 28192097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitochondrial dynamics and cell death in heart failure.
    Marín-García J; Akhmedov AT
    Heart Fail Rev; 2016 Mar; 21(2):123-36. PubMed ID: 26872674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathophysiology and Treatment Opportunities of Iron Deficiency in Heart Failure: Is There a Need for Further Trials?
    Tkaczyszyn M; Fudim M; Ponikowski P; Biegus J
    Curr Heart Fail Rep; 2023 Aug; 20(4):300-307. PubMed ID: 37428429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitochondrial Iron Metabolism: The Crucial Actors in Diseases.
    Duan G; Li J; Duan Y; Zheng C; Guo Q; Li F; Zheng J; Yu J; Zhang P; Wan M; Long C
    Molecules; 2022 Dec; 28(1):. PubMed ID: 36615225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.